Latest Lead News

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Trek Metals has raised $15 million through a strongly supported share placement to fund a major drilling campaign at its promising Kuro manganese discovery in Western Australia’s Kimberley region.

Lincoln Minerals is sharpening its focus on copper exploration with a renewed push at its Minbrie Project and new collaborations targeting base metals and graphite markets.

Asset Vision has reported a robust 38% increase in annual recurring revenue to $5.2 million in the first half of FY26, underpinned by new council contracts and AI-driven platform upgrades. The company’s positive cash EBITDA and strategic focus on scalable growth signal strong momentum in the critical infrastructure SaaS market.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

MLG Oz Limited reported a robust HY2026 with statutory net profit after tax soaring 73.2% to $7.1 million, driven by strong demand in the gold sector and operational resilience despite early weather setbacks and a safety fine.

MLG Oz Limited has delivered a robust half-year performance with revenue climbing 6% and EBITDA soaring 24.5%, underpinned by strong gold sector demand and operational efficiencies.

Li-S Energy has received the first $1.9 million tranche of a $7.8 million ARENA grant and appointed Hatch to lead a feasibility study for scaling up its lithium-sulfur battery manufacturing to 1 GWh capacity.

MLG Oz Limited reported a robust half-year with revenue up 5.3% to $287.2 million and net profit soaring 73.3% to $7.1 million, overcoming early weather disruptions and a significant safety fine.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

SEEK Limited reported robust H1 FY2026 results, powered by AI-driven product innovation and pricing, delivering strong revenue and profit growth alongside a record interim dividend. However, a significant impairment on its Zhaopin investment weighed on reported earnings.

SEEK Limited has reported a robust first half for FY2026, driven by AI-enhanced products and strategic pricing, resulting in double-digit revenue growth and a record interim dividend.